stockrow
Saturday 7 November 2026
Export AGEN’s income statement to Excel — free account
Agenus Inc.
AGEN Healthcare Biotechnology
Agenus Inc.’s revenue for fiscal 2025 (year ended December 2025) was $114.2 million, up 10.4% from fiscal 2024.
- Revenue
- +4.14%
- EPS
- −99.0%
- Free cash flow
- −37.1%
- Total debt
- −28.6%
Quarter to September 2026, against a year earlier
7.13
0.69
+10.71%
Follow AGEN
Alert me
| Sep '26 From the 10-Q filed 5 Nov | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
14.90 | 1.16 | 2.01 | 0.00 |
+8 more quarters Free account |
P/S ratio |
4.64 | 0.95 | 1.02 | 0.82 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(30.96) | (4.05) | (3.52) | (5.62) | |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
4.55 | 1.22 | 1.17 | 1.39 | |
EV/EBITDA |
11.21 | 3.94 | 9.34 | 0.00 | |
EV/Operating CF |
(5.87) | (1.64) | (1.66) | (2.05) | |
EV/FCF |
(5.89) | (1.64) | (1.67) | (2.06) | |
Quick Ratio |
0.33 | 0.32 | 0.36 | 0.03 | |
Current Ratio |
0.73 | 0.34 | 0.38 | 0.41 | |
Net Debt/EBITDA |
(3.57) | 0.96 | (0.31) | 2.78 | |
Debt/Assets |
9.95% | 17.41% | 16.19% | 19.69% | |
Debt/Equity |
(0.22) | (0.15) | (0.13) | (0.16) | |
Asset Turnover |
0.56 | 0.74 | 0.64 | 0.50 | |
Operating CF/Net income |
(13.20) | 51.65 | (0.92) | 1.56 | |
Capex/Depreciation |
0.00 | 0.46 | 0.05 | 0.00 | |
Interest Coverage |
0.79 | 0.74 | 1.03 | 0.90 | |
Research and Development Expense of Revenue |
36.99% | 42.76% | 35.04% | 21.96% | |
Selling, General and Administrative Expense of Revenue |
26.78% | 24.53% | 20.33% | 35.95% | |
Intangible Assets out of Total Assets |
0.11 | 0.16 | 0.15 | 0.12 | |
Share Based Compensation of Revenue |
9.34% | 10.45% | 3.25% | 10.12% | |
Graham Net Nets |
(0.34) | (2.37) | (2.52) | (3.98) | |
Graham Number |
0.00 | 0.00 | 0.00 | 9.17 | |
Earnings Yield |
6.71% | 86.48% | 49.70% | (12.74%) | |
Free Cash Flow Yield |
(16.64%) | (77.60%) | (68.76%) | (82.30%) | |
Revenue per Share |
0.50 | 0.84 | 0.89 | 1.15 | |
Operating CF per Share |
(0.32) | (0.75) | (0.95) | (0.56) | |
Capex per Share |
0.00 | 0.01 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.32) | (0.75) | (0.95) | (0.56) | |
Cash per Share |
1.07 | 0.45 | 0.92 | 0.10 | |
Shareholders Equity per Share |
(1.79) | (4.98) | (6.01) | (9.34) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(1.79) | (4.98) | (6.01) | (9.34) | |
Free Cash Flow |
(20.09) | (30.96) | (35.92) | (16.62) | |
Working Capital |
(55.38) | (153.01) | (153.95) | (190.05) | |
Capital Expenditures |
— | 0.24 | 0.03 | 0.00 | |
Net Current Asset Value |
(209.39) | (299.73) | (319.15) | (371.22) | |
EV/EBIT |
11.69 | 4.46 | 17.75 | 0.00 | |
Capex to Sales |
0.00 | (0.01) | 0.00 | 0.00 | |
Price to Operating Income |
11.93 | 3.49 | 15.46 | 0.00 | |
| Other line items | |||||
Average Receivables |
— | 27.96 | 27.21 | 3.71 | |
Average Payables |
65.99 | 66.69 | 67.66 | 72.23 | |
Average Assets |
239.72 | 178.96 | 193.33 | 226.53 | |
Average Common Equity |
(196.51) | (271.08) | (275.19) | (292.14) |
Columns are period end dates · fundamentals updated 5 Nov 2026